Upgrade to SI Premium - Free Trial

Summit Therapeutics (SMMT) Reiterated at Market Outperform by Citizens as AZN Invests $2B in Strategic Equity

September 30, 2026 4:34 AM
Citizens analyst Reni Benjamin reiterated a Market Outperform rating and $40.00 price target on Summit Therapeutics plc (NASDAQ: SMMT).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments